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Abstract
Objective: To determine whether inflammatory and hemostasis response in patients hospitalized for pneumonia varies by
age and whether these differences explain higher mortality in the elderly.
Methods: In an observational cohort of subjects with community-acquired pneumonia (CAP) recruited from emergency
departments (ED) in 28 hospitals, we divided subjects into 5 age groups (,50, 51–64, 65–74, 75–84, and $85). We measured
circulating levels of inflammatory (TNF, IL-6, and IL-10), hemostasis (D-dimer, Factor IX, thrombin-antithrombin complex,
antithrombin and plasminogen-activator inhibitor-1), and cell-surface markers (TLR-2, TLR-4, and HLA-DR) during the first
week of hospitalization and at discharge and compared 90-day mortality. We used logistic regression to compare odds
ratios (OR) for 90-day mortality between age groups, adjusting for differences in pre-infection factors alone and then
additionally adjusting for immune markers.
Results: Of 2,183 subjects, 495, 444, 403, 583, and 258 subjects were ,50, 51–64, 65–74, 75–84, and $85 years of age,
respectively. Large age-related differences were observed in 90-day mortality (0.82% vs. 3.2% vs. 6.4% vs. 12.8% vs. 13.6%,
p,0.01). No age-related differences in inflammatory and cell surface markers occurred during the first week. Older subjects
had higher pro-coagulant markers on ED presentation and over first week (p#0.03), but these differences were modest
(1.0–1.7-fold differences). Odds of death for older adults changed minimally in models incorporating differences in
hemostasis and inflammatory markers (for subjects $85 compared to those ,50, OR=4.36, when adjusted for pre-infection
factors and OR=3.49 when additionally adjusted for hemostasis markers). At discharge, despite clinical recovery as
evidenced by normal vital signs in .85% subjects, older subjects had modestly increased hemostasis markers and IL-6 levels
(p,0.01).
Conclusions: Modest age-related increases in coagulation response occur during hospitalization for CAP; however these
differences do not explain the large differences in mortality. Despite clinical recovery, immune resolution may be delayed in
older adults at discharge.
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Introduction
The incidence of severe sepsis and subsequent mortality among
individuals with community-acquired pneumonia (CAP) rises
sharply after the age of 65 [1,2]. For example, older individuals
hospitalized with CAP have a 10-fold increased risk of severe sepsis
and a 3-fold increase in 90-day mortality compared to younger
adults [3,4]. Older individuals who appear to have clinically
recovered after pneumonia hospitalization also have up to a 4-fold
higher mortality 1 year after hospital discharge [5,6]. The factors
underlying this phenomenon remain unclear and are not fully
explained by higher pre-infection chronic disease burden or illness
severity among the elderly [7,8].
Older age has been widely characterized as a ‘‘pro-inflamma-
tory’’ state [9,10]. Chronic elevation of inflammatory and
hemostasis markers has been implicated in many age-related
chronic conditions, ranging from frailty syndrome to heart failure
[11,12]. Animal and human experimental models of infection also
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13852suggest that older subjects have higher circulating levels of
inflammatory and coagulation-fibrinolysis response. For instance,
following cecal-ligation and puncture, old mice have a 7-fold
increase in circulating levels of tumor necrosis factor (TNF) and
interleukin (IL)-6, and these increases are associated with higher
mortality [13]. Similarly, it has been shown that old mice with
bacteremia have 3-fold higher levels of hemostasis markers than
young mice, which may contribute to age-related increase in
endotoxin-induced thrombosis [14,15]. Whether these differences
in immune response are observed in older adults hospitalized with
infection and explain age-related differences in outcome is unclear.
Understanding these differences in inflammatory and coagulation-
fibrinolysis response is important to design better therapeutic
interventions in the elderly.
We analyzed circulating inflammatory and hemostasis markers
in a large cohort of patients with CAP. We recruited patients on
their arrival to the Emergency Department (ED) to compare
circulating immune markers before the initiation of antibiotics and
other therapeutic interventions and during the first week of
hospitalization. We also examined these markers at hospital
discharge, when patients appeared to have clinically recovered
from infection, to compare age-related differences in resolution of
immune response. We hypothesized that age-related increases in
circulating inflammatory and coagulation-fibrinolysis response
would occur throughout the first week and at hospital discharge,
and that these differences would explain higher 90-day mortality
in the elderly.
Methods
Ethics Statement
The Institutional Review Boards at the following hospitals
approved the study: Pennsylvania: Allegheny General Hospital,
Jefferson Hospital/SHHS, Mercy Hospital, St. Clair Memorial
Hospital, St. Francis Medical Center, Sewickley Valley Hospital,
University of Pittsburgh Medical Center (UPMC) Braddock,
UPMC Horizon, UPMC Lee, UPMC McKeesport, UPMC
Passavant, UPMC Presbyterian, UMPC Shadyside, UPMC
Southside, UPMC St. Margaret, West Penn Hospital; Connecti-
cut: Bridgeport Hospital, Hartford Hospital, Milford Hospital,
New Britain General Hospital, Norwalk Hospital, Yale-New
Haven Hospital; Tennessee: Methodist Health Care (single IRB
approval for three Methodist University sites); Michigan: Henry
Ford Health System, Detroit Receiving/Sinai-Grace, Wayne
State. Written, informed consent was obtained from all partici-
pants or by proxy.
Subjects and design
We analyzed data from subjects enrolled in the Genetic and
Inflammatory Markers of Sepsis (GenIMS) study, a prospective
multicenter observational study [16]. GenIMS recruited subjects
from the emergency departments (ED) of 28 academic and
community hospitals in southwestern Pennsylvania, Connecticut,
southern Michigan, and western Tennessee. We enrolled adults 18
years or older who presented with CAP, as diagnosed by the
criteria of Fine et al [17]. Exclusion criteria included transfer from
another hospital, hospital discharge within the previous 10 days,
an episode of pneumonia within the past 30 days, chronic
mechanical ventilation dependency, cystic fibrosis, active pulmo-
nary tuberculosis, positive HIV antibody titer, alcoholism with
evidence of end-organ damage, admission for palliative care,
incarceration, and pregnancy. We enrolled 2320 subjects and
subsequently excluded 134 (6%) subjects for whom their treating
physicians ruled out CAP as their primary diagnosis, thus
restricting the analyses to 2183 subjects.
Clinical characteristics
We divided the subjects into five age groups: ,50 years, 50–64
years, 65–74 years, 75–84 years, and $85 years, which are
accepted geriatric age groups and have been used elsewhere in the
literature [18,19]. We gathered baseline clinical characteristics by
structured patient or proxy interviews, bedside assessment by study
nurses, and structured medical record reviews. We assessed
comorbidity using the Charlson comorbidity score [20]. Severity
of illness upon presentation was assessed using the Acute
Physiology and Chronic Health Evaluation III (APACHE III)
score [21] and the Pneumonia Severity Index (PSI) [17]. We also
assessed the acute physiology component of the APACHE III
score to compare physiologic derangements across different age
groups because age is not included in the calculation. We defined
severe sepsis as pneumonia plus acute organ dysfunction following
the 2001 International Consensus Criteria [22]. We defined acute
organ dysfunction as a new Sepsis-related Organ Failure
Assessment (SOFA) score of 3 or higher in any of 6 organ
systems, based on the international Sepsis Occurrence in the
Acutely ill Patient (SOAP) study [23]. We used blood and sputum
cultures to determine microbiologic etiology. Lower respiratory
tract secretions by bronchoscopy and pleural fluid cultures were
obtained in a very small subset and did not yield additional
information in our cohort. Strict criteria to define sputum quality
and to exclude skin contaminants in blood cultures based on
consensus guidelines were used [24]. Two reviewers reviewed all
microbiology results and independently assigned etiology. We
resolved any discrepancies by consensus and a third reviewer. We
assessed vital signs at hospital discharge to assess whether subjects
met criteria for clinical stability at hospital discharge, as described
by Halm et al [25].
Our primary clinical outcome was 90-day mortality. We also
compared 1-year mortality from hospital discharge in those who
survived the hospitalization because age-related differences in
immune response resolution, as evidenced by higher circulating
immune marker levels at hospital discharge, have been associated
with long-term mortality after discharge [26]. Mortality during
hospitalization and after hospital discharge was ascertained by
study nurses and the National Death Index search, respectively
[27].
Laboratory procedures
We assessed age-related differences in the immune response to
infection during hospitalization by comparing changes in circu-
lating concentrations of inflammatory (TNF, IL-6, IL-10),
coagulation (Factor IX, thrombin-antithrombin complexes
[TAT], antithrombin [AT]), and fibrinolysis (plasminogen activa-
tor inhibitor [PAI]-1 and D-dimer) systems. We assessed cell
surface marker expression on monocytes and granulocytes for
HLA-DR and toll-like receptor (TLR)-2 and TLR-4.
Day 1 blood samples were generally drawn immediately
following enrollment in the ED. Samples were not obtained in
the ED from subjects presenting after 11 PM, or on weekends and
holidays for logistic reasons. Subsequent blood samples were
collected at 8 AM daily for the first week and weekly thereafter
until hospital discharge or day 28. Each blood sample was drawn
into pyrogen-free vials containing heparin. Within one hour
plasma was separated by centrifugation and divided into four
1.5 ml tubes. Plasma was then frozen at 280uC and batched and
shipped on dry ice to our central laboratory.
Age and Immune Response to CAP
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the ED, we analyzed Day 1 inflammatory markers in 1410
subjects. Inflammatory marker concentrations were measured
using an automated chemiluminescent immunoassay analyzer
(IMMULITE, Diagnostic Products Corp., Los Angeles, CA),
thawing samples only once before assay. The minimal detectable
levels for TNF, IL-6 and IL-10 were 4 pg/ml, 2 pg/ml and 5 pg/ml,
respectively.
Day 1 hemostasis marker concentrations were analyzed in a
random subset of 725 subjects by a commercial laboratory
(Esoterix, Agoura Hills, CA). Specific methods and kits used were:
D-dimer, latex immunoassay (Diagnostica Stago, Parsipany, NJ,
USA); PAI-1, bioimmunoassay (Biopool Chromolize; Biopool
International, Ventura, CA, USA); antithrombin, chromogenic
(BioMerieux, Rho ˆne-Alpes, France); Factor IX, clot (BioMerieux);
and TAT, enzyme-linked immunosorbent assay (Behring, King of
Prussia, PA, USA). Abnormal values were defined by the clinical
laboratory or by manufacturer’s assay. These abnormalities
included: D-dimer .256 ng/ml, PAI-1 activity .31 IU/ml,
antithrombin activity ,70%, Factor IX activity ,60%, and
TAT .5.0 ng/ml.
Cell-surface markers were analyzed on ED presentation and on
the third and seventh day of hospitalization in a subset of 523
subjects enrolled in hospitals located within 60 miles of the
University of Pittsburgh because samples for cell-surface markers
require analysis within 48 hours. For cell-surface marker analyses,
we obtained fluorochrome- or biotin-conjugated antibodies from
eBioScience (San Diego, CA, USA) for TLR-2, TLR-4, and HLA-
DR. Antibodies were incubated with 100ml of whole blood for
15min at 4uC. Red blood cells were lysed, remaining cells were
washed, fixed, and stored at 24uC. Cell-surface marker data were
acquired within 48 hours of fixation on a BD FACS Vantage SE
flow cytometer (San Jose, CA, USA) and using BD CellQuest
software. Values for cell-surface markers are reported as the mean
channel fluorescence of cells positive for a given cell-surface
marker.
Table 1. Demographic and clinical characteristics stratified by age.
Characteristic ,50 (n=495) 50–64 (n=444) 65–74 (n=403) 75–84 (n=583) $85 (n=258)
Linear Trend
P value
Demographic characteristics
Sex male (%) 49.3 50.9 44.4 45.1 52.3 0.52
Race, white, n (%) 288 (58.2) 322 (72.5) 339 (84.1) 544 (93.3) 245 (95.0) ,0.001
Living Arrangement
Home, n (%) 472 (95.4) 420 (94.8) 378 (93.8) 507 (87.1) 182 (70.5) ,0.001
Personal care home, unskilled assistance, n (%) 2 (0.4) 5 (1.1) 7 (1.7) 19 (3.3) 30 (11.6) ,0.001
Nursing care home, n (%) 1 (0.2) 10 (2.3) 16 (4.0) 51 (8.8) 43 (16.7) ,0.001
Other, n (%) 20 (4.0) 8 (1.8) 2 (0.5) 5 (0.9) 3 (1.2) ,0.001
Activities of Daily Living
Fully independent and ambulatory, n (%) 445 (89.9) 338 (76.1) 271 (67.3) 312 (53.5) 74 (28.7) ,0.001
Mildly restricted, n (%) 45 (9.1) 89 (20.1) 103 (25.6) 199 (34.1) 104 (40.3) ,0.001
Housebound, n (%) 2 (0.4) 7 (1.6) 11 (2.7) 37 (6.4) 40 (15.5) ,0.001
Bed/chair bound, n (%) 3 (0.6) 10 (2.3) 18 (4.5) 35 (6.0) 40 (15.5) ,0.001
Comorbid conditions
{
Charlson score.0, n (%) 220 (44.4) 287 (64.6) 311 (77.2) 471 (80.8) 192 (74.4) ,0.001
Respiratory disease, n (%) 115 (23.2) 177 (39.9) 171 (42.4) 241 (41.3) 65 (25.2) 0.01
Renal disease, n (%) 15 (3.0) 16 (3.6) 11 (2.7) 8 (1.37) 1 (0.4) 0.003
Cardiac disease, n (%) 22 (4.9) 69 (17.7) 132 (37.7) 210 (41.4) 80 (33.9) ,0.001
Diabetes, n (%) 58 (11.7) 86 (19.4) 95 (23.6) 121 (20.8) 54 (20.9) 0.003
Neoplastic disease, n (%) 11 (2.2) 27 (6.1) 31 (7.7) 43 (7.4) 20 (7.8) 0.003
Ever smoked, n (%) 316 (64.1) 314 (71.4) 289 (72.4) 377 (65.1) 112 (44.3) ,0.001
Symptoms and therapy prior to hospitalization
Duration of symptoms prior to hospitalization,
mean (median, sd)
5.4 (3.0,8.1) 5.8 (3.0,8.1) 4.4 (3.0,6.4) 4.5 (3.0,6.8) 3.8 (2.0,4.9) 0.01
Received antibiotics within 7 days, n (%) 92 (18.6) 79 (17.8) 66 (16.4) 96 (16.5) 37 (14.5) 0.14
Severity of illness
PSI class$IV, n (%) 16 (3.2) 75 (16.9) 137 (34.0) 305 (52.3) 183(70.9) ,0.001
APACHE III, mean (median, sd) 35.8 (34, 19.2) 45.9 (45, 17.1) 56.9 (56, 15.5) 61.4 (59, 15.8) 68.1 (66, 15.3) ,0.001
Acute physiology score, mean (median, sd)
{ 31.9 (32, 16) 36.7 (36, 15) 39.7 (38, 15) 41.4 (39, 14) 41.9 (40, 14) 0.30
Hospital length of stay, mean (median, sd) 4.8 (4, 5) 6.7 (5, 6) 6.7 (6, 5) 7.5 (6, 5) 7.7 (6, 6) 0.96
APACHE=Acute Physiology and Chronic Health Evaluation; PSI=Pneumonia Severity Index.
{Less than 2% of subjects reported pre-existing cirrhosis or AIDS.
{Acute physiology score derived from APACHE III score.
doi:10.1371/journal.pone.0013852.t001
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hospital discharge in those who were alive at hospital discharge in
1739 and 893 subjects, respectively. For most subjects samples
were measured within 48 hours of hospital discharge (83%). For a
minority of subjects (7%), the last available cytokine concentration
measurement was more than 96 hours before discharge.
Statistical analyses
Statistical analysis was performed using SAS software, version
9.1 (SAS Institute, Cary, NC) with statistical significance set at
p,0.05. We conducted univariate comparisons of clinical
characteristics, risk of severe sepsis, organ dysfunction, and
mortality for subjects in the five age groups using chi-square tests
or Kruskal-Wallis tests where appropriate as well as linear trend
tests.
We compared differences in immune response to infection,
comparing immune markers in subjects in the five age groups at
Day 1, during the first week of hospital stay, and at hospital
discharge. We used Tobit models to account for marker levels
below detection threshold and ANOVA and linear trend tests to
assess age-related differences in levels in the ED and at hospital
discharge [28]. For longitudinal analyses over the first week, we
used regression analysis with mixed models to account for
correlation of these markers over time. We assumed a log-normal
distribution for marker concentrations. P values shown are
adjusted for sex, race, comorbidity, and smoking status. We
assessed whether discrete inflammatory cytokine patterns (IL-6:IL-
10 ratio) existed among age groups over the first week because
prior studies have suggested that older adults have a preponder-
ance of either pro-inflammatory or anti-inflammatory cytokine
activation, also known as immunologic dissonance [29,30,31]. We
previously showed that for longitudinal analysis of IL-6:IL-10
patterns, 3 group models (high, medium, and low concentrations)
with a quadratic trend for each group exhibited the best fit [16].
We used these models and determined the frequency of different
IL-6:IL-10 patterns for each age group [32]. We determined
unadjusted and adjusted odds ratios (OR) for 90-day mortality
using logistic regression models, adjusting for sex, race, smoking
status, and Charlson comorbidity score. We then additionally
adjusted for total burden of coagulation abnormalities measured
on ED presentation because hemostasis markers differed across
age groups. We assigned one point for each hemostasis
abnormality and input the total score (0–5) into the model.
We conducted three sensitivity analyses. First, to assess whether
age-related differences between onset of symptoms of pneumonia
and the time to ED presentation confounded our results, we
analyzed a subgroup of subjects who reported having arrived to
the ED within a day of onset of symptoms. Second, we stratified
our Day 1 analyses of IL-6 and D-dimer by presence or absence of
severe sepsis to determine if an age-related immune response
occurred among those who were most severely ill. Third, we
repeated our analyses of IL-6 and D-dimer in subjects with similar
etiology based on procalcitonin (PCT) stratification, since patients
with high PCT ($0.25 ng/ml) levels are more likely to have
bacterial pneumonia [33]. PCT was measured using a time-
resolved, amplified cryptate emission assay (Kryptor PCt,
BRAHMS, Hennigsdorf, Germany) [34]. For sensitivity analyses,
we analyzed three age groups: ,65, 65–74, and $75 due to
reduced sample sizes.
Results
Demographic and clinical characteristics
Table 1 shows the demographic and clinical characteristics for
the 2183 subjects stratified by age group. Of the 2183 subjects, 495
(22.7%), 444 (20.3%), 403 (18.5%), 583 (26.7%), and 258 (11.8%)
were ,50, 51–64, 65–74, 75–84, and $85 years of age,
respectively. The age range was 18–101 years, with a mean age
of 67.2 years, and there were similar proportions of men and
Table 2. Hospital outcome and mortality stratified by age.
Variable ,50 50–64 65–74 75–84 $85 Linear Trend P value
Risk of severe sepsis and organ dysfunction
Severe sepsis, n (%) 73 (14.8) 102 (23.0) 106 (26.3) 198 (34.0) 109 (42.3) ,0.001
Respiratory dysfunction, n (%) 45 (9.1) 72 (16.2) 69 (17.1) 106 (18.2) 42 (16.3) 0.001
Cardiac dysfunction, n (%) 11 (2.2) 23 (5.2) 9 (2.2) 27 (4.6) 5 (1.9) 0.76
Renal dysfunction, n (%) 30 (6.1) 47 (10.6) 53 (13.2) 124 (21.3) 77 (29.8) ,0.001
Liver dysfunction, n (%) 2 (0.4) 2 (0.5) 1 (0.3) 4 (0.7) 3 (1.2) 0.24
CNS dysfunction, n (%) 12 (2.4) 20 (4.5) 24 (6.0) 41 (7.0) 17 (6.6) 0.001
Coagulation dysfunction, n (%) 1 (0.2) 6 (1.4) 5 (1.2) 8 (1.4) 5 (1.9) 0.04
Mortality from ED admission
Hospital mortality, n (%) 5 (1.0) 5 (1.1) 13 (3.2) 43 (7.4) 22 (8.5) ,0.001
90-day, n (%) 4 (0.8) 12 (2.7) 24 (6.2) 63 (11.7) 29 (12.3) ,0.001
Mortality after hospital discharge
1-year, n (%) 17 (3.5) 35 (8.0) 62 (15.9) 130 (24.1) 75 (31.8) ,0.0001
Location after Discharge
Home, n (%) 335 (91.3) 295 (84.8) 283 (76.3) 360 (64.0) 109 (44.1) ,0.0001
Acute or sub-acute care facility, n (%) 9 (2.5) 27 (7.8) 29 (7.8) 71 (12.6) 30 (12.2) ,0.0001
Assisted living facility, n (%) 6 (1.6) 15 (4.3) 38 (10.2) 83 (14.8) 82 (33.2) ,0.0001
Other, n (%) 17 (4.6) 11 (3.2) 21 (5.7) 48 (8.5) 26 (10.5) 0.06
ED=Emergency Department.
doi:10.1371/journal.pone.0013852.t002
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chronic disease compared to younger subjects, as evidenced by a
higher Charlson score (p,0.001). Older adults were more likely to
be in an assisted-living home and have restrictions on activities of
daily living (ADL) (p,0.001). There was no age-related difference
in the likelihood of receiving antibiotics in the week prior to ED
arrival (p=0.65). On average, older subjects experiencing
symptoms presented to the ED 1–2 days earlier than younger
subjects (p,0.001). Older subjects were more likely to have severe
CAP upon presentation, as evidenced by greater proportion of
older adults with a Pneumonia Severity Index score $IV and by a
higher Acute Physiology and Chronic Health Evaluation
(APACHE III) score (p,0.001 for both). Subjects stayed an
average of 7 days in the hospital, with those $85 years staying on
average 3 days longer than those ,50 years.
Blood or sputum cultures to determine microbiologic etiology
were obtained in 1606 (74%) subjects within 48 hours of ED
presentation. An etiologic agent was identified in only 186 (12%)
of these subjects, with 110 (59%) identified as Gram-positive, 64
(35%) identified as Gram-negative, and 12 (6%) identified as
mixed. Among subjects ,65, 65–74, and $75, older subjects were
more likely to have obtained a culture (65% vs. 78% vs. 81%) and
similarly likely to have an etiologic agent identified (9% vs. 10% vs.
8%) (p,0.01 and p=0.61, respectively). Older subjects tended to
have a higher proportion of Gram-negative organisms compared
to younger subjects (26% vs. 26% vs. 49% per increasing age
group, respectively, with percentages totaling more than 100%
because some subjects had more than one etiologic agent
identified). A similar age-related trend was not seen in the
proportion of Gram-positive organisms identified (50% vs. 18% vs.
30%).
Older subjects have higher risk of severe sepsis and
mortality
Severe sepsis occurred in a fourth of subjects (n=588, Table 2).
Compared to younger subjects, older subjects had a higher risk of
severe sepsis (p,0.001), with those $85 years having a 2.8-fold
increased risk of severe sepsis compared to those ,50 years (42.3%
vs. 14.8%, p,0.01). Older subjects were also more likely to
develop respiratory, renal, neurological, and coagulation dysfunc-
tion while hospitalized (p#0.02).
Older subjects had higher mortality during hospitalization and
at 90 days after ED arrival (p,0.001 for all time points).
Compared to subjects ,50 years, those $85 years had an 8-fold
increased hospital mortality (1.0% vs. 8.5%) and a 17-fold
increased 90-day mortality (0.8% vs. 13.6%). Among survivors
Figure 1. A modest pro-coagulant response was seen in older subjects upon ED admission (Day 1) and during the first week of
hospitalization. There was an age-related increase in mean values of hemostasis markers D-dimer and thrombin-antithrombin complex (TAT) and
an age-related decrease in F-IX, plasminogen-activator inhibitor-1 (PAI-1), and antithrombin (AT). Pa are p values from ANOVA or Tobit models
adjusted for sex, race, comorbidity, and smoking status to compare differences in mean levels of markers on Day 1 across different age groups. Pb are
p values for linear trend tests for markers on Day 1, adjusted for sex, race, comorbidity, and smoking status. Pc are p values from mixed effects model
adjusted for sex, race, comorbidity, and smoking status to compare mean levels over the first week.
doi:10.1371/journal.pone.0013852.g001
Age and Immune Response to CAP
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13852of CAP, there was also an age-related increase in mortality up to 1-
year after discharge (p,0.001), with those $85 years having a 9-
fold increase in mortality compared to those ,50 years (31.8% vs.
3.5%) (Table 2).
Differences in early immune response
An age-related pro-coagulant response occurred in subjects
upon arrival to the ED and continued throughout the first week of
hospitalization. In multivariate analyses, subjects at ED presenta-
tion (Day 1) had age-related increases in circulating (mean)
concentration of D-dimer (p,0.001) and TAT (p,0.001) and age-
related decreases in PAI-1 (p=0.02), AT (p=0.03), and F-IX
(p=0.001) (Figure 1). With the exception of AT (linear trend
p=0.08), hemostasis markers showed a linear relationship with
age (chi square for trend p,0.01 for all other markers, Figure 1).
Numerically, these differences were modest: compared to those
,50 years, subjects $85 years had 1.6-fold and 1.5-fold increases
in D-dimer and TAT, respectively, and had 1.4-fold, 1.0-fold, and
1.2-fold decreases in PAI-1, AT, and F-IX, respectively. Mean
values of AT increased over the first week, whereas the other four
hemostasis markers had no clear trajectory. The age-related
differences in mean concentration levels of all hemostasis markers
at Day 1 persisted over the first week (all p,0.01, Figure 1).
Circulating mean concentration levels of inflammatory markers
IL-6, IL-10, and TNF and cell surface markers TLR-2, TLR-4,
and HLA-DR were similar across different age groups on Day 1
and over the first week, respectively (Figures 2 and 3). Notable
trajectories over the first week were IL-6 and IL-10, which both
decreased sharply over the first three days. The frequency of IL-
6:IL-10 groupings showed similar cytokine patterns across age
groups (p=0.32, Table 3). Over 70% of subjects in each age group
were in either the low IL-6: low IL-10, medium IL-6: low IL-10, or
medium IL-6: medium IL-10 category.
Our analyses of hemostasis and inflammatory markers were not
affected by time between the onset of symptoms of pneumonia and
ED presentation, presence or absence of severe sepsis, or in
subjects with PCT$0.25. Among subjects who arrived to the ED
within 24 hours of symptom onset, we found an age-related
increase in mean levels D-dimer (p=0.01) and no age-related
difference in levels of IL-6 (p=0.85). Likewise, in subjects with and
without severe sepsis as well as in subjects with PCT$0.25, there
was an age-related increase in D-dimer (p=0.02, ,0.01, and 0.02,
respectively) and no age-related difference in IL-6 (p=0.86, 0.42,
and 0.53, respectively) (Table 4).
Table 5 shows ORs for the association of age group and 90-day
mortality adjusted for pre-infection factors, such as demographics,
chronic diseases, and smoking, and adjusted for pre-infection
factors plus Day 1 hemostasis abnormalities. Compared to those
less than 50 years, there was a higher risk of 90-day mortality in
the 75–84 year (OR=4.99; 95%CI=1.46–17.13; p=0.01) and
$85-year (OR=4.36; 95% CI=1.19–15.97; p=0.03) age groups
when adjusted for baseline covariates. The ORs changed
Figure 2. No differences were found in the mean values of inflammatory (TNF, IL-6, and IL-10) markers when stratified by age
group. Markers were measured upon presentation to the ED and over the first week of hospitalization. Pa are p values from Tobit models adjusted
for sex, race, comorbidity, and smoking status to compare differences in mean levels of markers on Day 1 across different age groups. Pc are p values
from mixed effects model adjusted for sex, race, comorbidity, and smoking status to compare mean levels over the first week.
doi:10.1371/journal.pone.0013852.g002
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ities in 75–84 year (OR=4.79; 95% CI=1.36–16.90; p=0.01) or
the $85-year (OR=3.49; 95% CI=0.93–13.11; p=0.06) age
groups.
Differences in immune resolution at hospital discharge
Across all age groups, most subjects were discharged to home
(Table 2). However, older adults were more likely to be transferred
to an acute or sub-acute care facility or a nursing home upon
discharge. Most subjects met the Halm criteria for clinical stability
on the day of discharge. Only 15 (2%), 73 (8%), 24 (3%), and 8
(1%) subjects had a temperature higher than 37.8uC, heart rate
higher than 100/minute, respiratory rate higher than 24/minute,
or systolic blood pressure ,90 mm of Hg, respectively. Older
adults were more likely to have all 4 vital signs returned to normal
at discharge (81% vs. 85% vs. 87% vs. 90% vs. 90%) (p,0.01) and
were equally likely to be discharged with 2 or more abnormal vital
signs (3% vs. 3% vs. 2% vs. 1% vs. 1%) (p=0.3).
An age-related pro-coagulant response was observed in
survivors upon hospital discharge (Table 6). In multivariate
analysis, older subjects had significantly increased levels of D-
dimer (p,0.001) and TAT (p=0.01) and significantly decreased
levels of PAI-1 (p=0.002), AT (p,0.001), F-IX (p,0.001). All
coagulation markers showed a linear relationship with age
(p,0.01). Compared to those ,50 years, subjects $85 years
had 1.2-fold and 1.4-fold increases in D-dimer and TAT,
respectively, and 1.3-fold, 1.1-fold, and 1.2-fold decreases in
PAI-1, AT, and F-IX, respectively.
Despite similar levels of inflammatory markers at ED presen-
tation, subjects at hospital discharge showed an age-related
Figure 3. No differences were found in expression of cell surface markers when stratified by age group. Markers were measured upon
ED presentation and at days 3 and 7. Values for cell surface markers are reported as mean channel fluorescence (MCF) of cells positive for a given cell
surface marker. Pa are p values from ANOVA models adjusted for sex, race, comorbidity, and smoking status to compare differences in mean levels of
markers on Day 1 across different age groups. Pc are p values from mixed effects model adjusted for sex, race, comorbidity, and smoking status to
compare mean levels on Days 1, 3, and 7.
doi:10.1371/journal.pone.0013852.g003
Table 3. Frequency (%) of group membership of IL-6:IL-10
patterns based on trajectory analysis over the first week of
hospitalization.
IL-6:IL-10 patterns
Age L:L L:M L:H M:L M:M M:H H:L H:M H:H
,50 28.78 6.82 1.19 35.91 12.17 3.56 2.97 6.23 2.37
50–64 28.76 7.80 0.54 34.68 13.98 2.96 3.76 4.30 3.23
65–74 28.38 9.46 2.16 32.70 13.51 2.97 2.70 5.41 2.70
75–84 22.78 9.61 1.60 35.94 13.70 4.27 4.09 4.98 3.02
$85 22.45 3.27 1.22 40.41 15.92 5.71 1.63 6.53 2.86
L=low; M=medium; H=high.
Distribution of IL-6:IL-10 sub-groupings did not differ across age group
(P=0.32).
doi:10.1371/journal.pone.0013852.t003
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related with age (p,0.001). Compared to those ,50 years,
subjects $85 years had a 1.2-fold increase in IL-6. Mean
concentrations of inflammatory markers IL-10 and TNF were
similar across age groups at discharge.
Discussion
Surprisingly, unlike the large age-related differences in circu-
lating inflammatory and coagulation-fibrinolysis response seen in
animal models of infection, we did not observe differences in
circulating inflammatory response and showed only modest
differences coagulation-fibrinolysis response between older and
younger subjects hospitalized for CAP. The modest differences in
hemostasis markers did not explain the large age-related
differences in mortality. Our results remained unchanged when
repeated to account for differences in time between the onset of
symptoms and hospitalization, and in subgroups with and without
severe sepsis. Furthermore, we did not observe differences in anti-
inflammatory response, as evidenced by similar levels of IL-10 and
in IL-6:IL-10 ratios across different age groups. We did show age-
related differences in immune resolution among survivors of CAP,
with older subjects having a pro-inflammatory and pro-coagulant
response compared to younger subjects at hospital discharge.
These findings have important implications for understanding age-
related differences in long-term outcomes of sepsis.
Large-related differences in 90-day mortality occurred among
our subjects despite a similar circulating immune response to
pneumonia during hospitalization. There are several explanations
for this occurrence, including potential immune response differ-
ences that occurred prior to hospitalization and possible
differences that occurred at the tissue level and were not measured
in our study. However, we speculate that the large differences in
early outcome in our subjects are likely driven by underlying frailty
in the older population, which is characterized by vulnerability to
acute stressors and is a consequence of decline in overall function
and physiologic reserve [35]. In the U.S., nearly 7% of those over
65 and 30% over 80 years are considered frail [36]. In our cohort,
Table 4. Day 1 mean and median levels of D-dimer (ng/ml) and IL-6 (pg/ml) stratified by severe sepsis, PCT, and those who arrived
to ED within 24 hours of symptom onset.
Marker ,65 65–74 $75 Linear Trend P value
Severe sepsis
D-dimer, mean, median (n) 589.9, 658.5 (58) 749.9, 772.8 (41) 925.2, 1032.8 (135) 0.26
IL-6, mean, median (n) 76.7, 69.4 (116) 67.4, 79.8 (71) 83.1, 65.4 (239) 0.43
No severe sepsis
D-dimer, mean, median (n) 502.7, 445.9 (168) 492.7, 454.9 (121) 645.5, 607.9 (201) 0.01
IL-6, mean, median (n) 49.4, 40.4 (388) 40.0, 33.8 (199) 43.8, 39.6 (397) 0.56
PCT$0.25
D-dimer, mean, median (n) 665.1, 678.6 (115) 685.4, 652.0 (75) 897.8, 1002.2 (146) 0.04
IL-6, mean, median (n) 145.5, 131.6 (241) 121.5, 107.8 (130) 139.8, 112.2 (275) 0.47
Arrival to ED within 24 hours of
symptom onset
D-dimer, mean, median (n) 391.5, 301.9 (53) 523.2, 572.5 (61) 796.3, 804.3 (128) 0.01
IL-6, mean, median (n) 75.9, 65.4 (116) 77.5, 66.7 (102) 80.6, 62.2 (244) 0.85
PCT=procalcitonin; ED=emergency department.
doi:10.1371/journal.pone.0013852.t004
Table 5. Unadjusted and adjusted odds ratios for association between age and mortality at 90 days.
Odds Ratio (95% CI)
Age Unadjusted P value Adjusted
{ P value
Adjusted with Day 1
hemostasis abnormalities
{ P value
,50 Referent Referent Referent
50–64 0.96 (0.21–4.37) 0.95 0.71 (0.15–3.34) 0.67 0.81 (0.17–3.92) 0.80
65–74 2.66 (0.74–9.60) 0.13 1.86 (0.50–6.92) 0.36 2.15 (0.56–8.20) 0.26
75–84 7.42 (2.25–24.52) 0.01 4.99 (1.46–17.13) 0.01 4.79 (1.36–16.90) 0.01
$85 6.20 (1.77–21.81) 0.01 4.36 (1.19–15.97) 0.03 3.49 (0.93–13.11) 0.06
CI=confidence interval.
{Adjusted for sex, race, comorbidity, and smoking status.
{Adjusted for sex, race, comorbidity, and smoking status, plus hemostasis abnormalities defined as follows: D-dimer .256 ng/ml, PAI-1 activity .31 IU/ml,
Antithrombin activity ,70%, Factor IX activity ,60%, and TAT .5.0 ng/ml.
doi:10.1371/journal.pone.0013852.t005
Age and Immune Response to CAP
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13852over 30% of subjects $85 reported significant impairment in
activities of daily living, which is a crude marker for frailty [37].
Our results show that older subjects had increased organ
dysfunction and severe sepsis despite small differences in
circulating inflammatory and coagulation-fibrinolysis response,
suggesting that older adults may have increased susceptibility to
end-organ damage by inflammatory and coagulant mediators than
younger adults.
Large age-related differences in mortality persisted among
survivors of CAP hospitalization at 1-year after hospital discharge.
Prior studies and our results suggest that the higher mortality after
hospital discharge among older adults is not explained by higher
burden of chronic diseases prior to infection [38]. We found a
modest age-related increase in inflammatory and hemostasis
markers at discharge, despite apparent clinically recovery from
pneumonia. Although we could not measure pre-infection
inflammatory and hemostasis markers in our subjects, the marker
levels found at discharge are at least 4-fold higher than have been
reported at baseline in community-dwelling individuals with
similar ages, suggesting an unresolved immune response in our
subjects [38,39,40]. We speculate that a persistent pro-inflamma-
tory and pro-coagulant state during recovery among older adults
may explain higher risk of long-term sequelae among the elderly
[41,42,43].
Prior studies have shown increased PAI-1 levels in older
adults and among those with higher illness severity following an
infection [15,44,45]. Although older subjects were more severely
ill, we observed lower circulating PAI-1 levels among older
subjects in our study. Potential reasons for lower circulating
PAI-1 concentrations in the elderly include downregulation of
PAI-1 expression due to sustained IL-10 expression and age-
related changes in tensile strength of tissues and cells, which
have been shown to decrease PAI-1 expression [46,47]. Our
findings are consistent with a recent study of elderly patients
with periodontal disease, where PAI-1 was unique among
hemostasis markers in being lower among those with severe
periodontal disease [48].
Our study has three major strengths. First, unlike similar cross-
sectional studies [18,49,50], we measured immune markers on ED
presentation and during hospital course, and were thus able to
compare both the initial immune response in patients at the time
of ED presentation and its subsequent trajectory. In most subjects,
samples were obtained in the ED prior to initiation of antibiotic
therapy and other interventions. Thus our results are less likely to
be confounded by therapeutic interventions. Second, we analyzed
a large multicenter cohort of subjects with a single infectious
disease, CAP. We chose CAP because it is the most common
infectious cause of hospitalization in developed countries and the
most common cause of severe sepsis [1,51]. Our results are thus
generalizable and less likely to be confounded by differences in
source of infection. Third, we measured expression of TLR-2,
TLR-4, and HLA-DR because these receptors are integral
components of the host response to infection and are involved in
activating the inflammatory and coagulant response to infection
[52,53,54]. Our finding that all three cell surface markers
remained similar across age groups corroborates and strengthens
our analysis of little or no differences in inflammatory or
coagulation-fibrinolysis response.
Our findings have limitations. First, due to practical reasons we
did not assess the immune response prior to hospitalization. Larger
differences in immune response may occur during this period and
likely lead to higher risk of hospitalization among older adults.
Second, we could not fully assess whether our results were
confounded due to potential age-related differences in infectious
etiology. We obtained a low yield of bacterial cultures in our
subjects, which is consistent with previous large studies of CAP
patients and is likely due to poor yield of current culture
techniques [55]. We therefore repeated key analyses stratified by
high PCT level to compare subjects who are more likely to have
bacterial infection, and showed that inflammatory and coagulation
marker patterns were similar in this subset.
In conclusion, our results suggest that, once hospitalized for
CAP, there is little age-related difference in circulating immune
response. The differences in coagulation-fibrinolysis response that
exist do not explain the large differences in outcome observed
between younger and older adults. Finally, older patients who
survive CAP may have delayed immune resolution compared to
younger patients.
Table 6. Mean values of inflammation and hemostasis markers prior to discharge from hospital show a modest age-related
increase in inflammation and coagulant response.
Markers ,50yrs 50–64yrs 65–74yrs 75–84yrs $85yrs
ANOVA P
value
{ Linear Trend P value
{
Inflammation (pg/ml)
TNF 6.6 6.2 6.4 6.5 6.3 0.27 0.10
IL-6 9.8 10.1 10.8 10.8 11.8 0.02 ,0.001
IL-10 6.0 5.8 5.9 5.8 5.9 0.83 0.69
Hemostasis
D-dimer (ng/ml) 607.9 550.0 518.0 727.8 699.2 ,0.001 0.009
PAI-1 (IU/ml) 5.8 5.5 4.7 4.0 4.3 0.002 0.002
F-IX (%) 126.5 134.3 119.1 107.8 106.7 ,0.001 ,0.001
TAT (ng/ml) 3.2 3.3 3.7 3.8 4.5 0.01 ,0.001
AT (%) 97.5 96.5 91.8 88.2 85.6 ,0.001 ,0.001
F-IX=Factor IX; PAI-1=plasminogen-activator inhibitor-1; TAT=thrombin-antithrombin complex; AT=antithrombin.
{P values from ANOVA or Tobit models adjusted for sex, race, comorbidity, and smoking status.
{P values from linear trend test adjusted for sex, race, comorbidity, and smoking status.
doi:10.1371/journal.pone.0013852.t006
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